ArticleAnnals of laboratory medicine2016
Prevalence and Molecular Characteristics of Carbapenemase-Producing Enterobacteriaceae From Five Hospitals in Korea.
Article in Annals of laboratory medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Antimicrobial Resistance - The 'Real' Pandemic We Are Unaware Of, Yet Nearby.Journal of Korean medical science · 2025Review
- A Nationwide Genomic Study of Clinical Klebsiella pneumoniae CarryingMicrobiology spectrum · 2023Article
- Clinical carbapenem-resistantFrontiers in cellular and infection microbiology · 2022Article
- Comparative Genomics Revealed Fluoroquinolone Resistance Determinants and OmpF Deletion in Carbapenem-ResistantFrontiers in microbiology · 2022Article
- Genotypic Distribution and Antimicrobial Susceptibilities of Carbapenemase-ProducingAnnals of laboratory medicine · 2022Article
- Alteration of Gut Microbiota in Carbapenem-Resistant Enterobacteriaceae Carriers during Fecal Microbiota Transplantation According to Decolonization Periods.Microorganisms · 2021Article
- Prolonged Carriage of Carbapenemase-ProducingJournal of clinical medicine · 2021Article
- Molecular Analysis and Antimicrobial Resistance Pattern of Tigecycline-Non-SusceptibleInfection and drug resistance · 2021Article
- Molecular Characterization of Carbapenemase-ProducingInfection and drug resistance · 2021Article
- Spontaneous bacterial peritonitis due to carbapenemase-producingWorld journal of hepatology · 2020Review
- Xpert Carba-R assay for detection of carbapenemase-producing organisms in patients admitted to emergency rooms.Medicine · 2020Observational
- Molecular epidemiology and mechanisms of tigecycline resistance in carbapenem-resistant Klebsiella pneumoniae isolates.Journal of clinical laboratory analysis · 2020Article
- Risk Factors for Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2020Article
- Profile of Enterobacteria Resistant to Beta-Lactams.Antibiotics (Basel, Switzerland) · 2020Article
- Rapid Identification of OXA-48-like, KPC, NDM, and VIM Carbapenemase-Producing Enterobacteriaceae From Culture: Evaluation of the RESIST-4 O.K.N.V. Multiplex Lateral Flow Assay.Annals of laboratory medicine · 2020Article
- The Global Ascendency of OXA-48-Type Carbapenemases.Clinical microbiology reviews · 2019Review
- Clonal Spread of Extended-Spectrum Cephalosporin-ResistantFrontiers in microbiology · 2019Article
- Resistance mechanisms and molecular epidemiology of carbapenem-nonsusceptibleInfection and drug resistance · 2019Article
- The Infinity War: How to Cope with Carbapenem-resistantJournal of Korean medical science · 2018Review
- NDM-5 and OXA-48 Co-producing Uropathogenic Escherichia coli Isolate: First Case in Korea.Annals of laboratory medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe emergence of carbapenemase-producing Enterobacteriaceae (CPE) represents a major clinical problem because these bacteria are resistant to most antibiotics. CPE remain relatively uncommon in Korea. We report the prevalence, clinical characteristics, and molecular epidemiology of CPE isolates collected from five university hospitals in Korea.
methodsBetween January and December 2015, 393 non-duplicated isolates that were nonsusceptible to ertapenem were analyzed. Production of carbapenemase, extended-spectrum β-lactamase, and AmpC β-lactamase was determined by genotypic tests. Antimicrobial susceptibility profiles were determined by using an Etest. Clonality of Klebsiella pneumoniae carbapenemase (KPC)-2-producing and oxacillinase (OXA)-232-producing Klebsiella pneumoniae isolates was determined by pulsed-field gel electrophoresis (PFGE).
resultsOf the 393 isolates tested, 79 (20.1%) were CPE. Of these 79 isolates, 47 (59.5%) harbored the bla(OXA-232) gene while the remaining isolates carried genes bla(KPC-2) (n=27), bla(IMP-1) (n=4), and bla(NDM-1) (n=1). Among the 24 KPC-2 K. pneumoniae isolates from hospital B, 100% were resistant to carbapenems, 8% to colistin, and 0% to tigecycline. Among the 45 OXA-232 K. pneumoniae at hospital C, 95% were resistant to ertapenem, 68% to imipenem, 95% to meropenem, 10% to colistin, and 24% to tigecycline. PFGE analysis revealed a unique pattern for KPC-2 K. pneumoniae and identified 30 isolates belonging to the dominant pulsotypes (PT)1 and PT2 among 41 OXA-232 K. pneumoniae isolates.
conclusionsCPE strains are present in Korea, with the majority of K. pneumoniae isolates producing OXA-232 and KPC-2. The prevalence and predominant genotypes of CPE show hospital-specific differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.